Vaxcell-Bio Therapeutics (Korea) Probability of Future Stock Price Finishing Over 12828.64
| 323990 Stock | KRW 11,170 600.00 5.68% |
Vaxcell-Bio |
Vaxcell-Bio Therapeutics Target Price Odds to finish over 12828.64
The tendency of Vaxcell-Bio Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over W 12,829 or more in 90 days |
| 11,170 | 90 days | 12,829 | about 63.09 |
Based on a normal probability distribution, the odds of Vaxcell-Bio Therapeutics to move over W 12,829 or more in 90 days from now is about 63.09 (This Vaxcell Bio Therapeutics Co probability density function shows the probability of Vaxcell-Bio Stock to fall within a particular range of prices over 90 days) . Probability of Vaxcell-Bio Therapeutics price to stay between its current price of W 11,170 and W 12,829 at the end of the 90-day period is about 33.96 .
Assuming the 90 days trading horizon Vaxcell-Bio Therapeutics has a beta of 0.22. This suggests as returns on the market go up, Vaxcell-Bio Therapeutics average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Vaxcell Bio Therapeutics Co will be expected to be much smaller as well. Additionally Vaxcell Bio Therapeutics Co has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Vaxcell-Bio Therapeutics Price Density |
| Price |
Predictive Modules for Vaxcell-Bio Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Vaxcell-Bio Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Vaxcell-Bio Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Vaxcell-Bio Therapeutics is not an exception. The market had few large corrections towards the Vaxcell-Bio Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Vaxcell Bio Therapeutics Co, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Vaxcell-Bio Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.55 | |
β | Beta against Dow Jones | 0.22 | |
σ | Overall volatility | 1,067 | |
Ir | Information ratio | -0.25 |
Vaxcell-Bio Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Vaxcell-Bio Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Vaxcell-Bio Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Vaxcell-Bio Therapeutics generated a negative expected return over the last 90 days | |
| Net Loss for the year was (4.76 B) with loss before overhead, payroll, taxes, and interest of (5.39 M). | |
| Vaxcell Bio Therapeutics Co has accumulated about 27.31 B in cash with (4.66 B) of positive cash flow from operations. | |
| Roughly 14.0% of the company shares are owned by insiders or employees |
Vaxcell-Bio Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Vaxcell-Bio Stock often depends not only on the future outlook of the current and potential Vaxcell-Bio Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Vaxcell-Bio Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 15.2 M | |
| Cash And Short Term Investments | 27.3 B | |
| Shares Float | 9 M |
Vaxcell-Bio Therapeutics Technical Analysis
Vaxcell-Bio Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Vaxcell-Bio Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Vaxcell Bio Therapeutics Co. In general, you should focus on analyzing Vaxcell-Bio Stock price patterns and their correlations with different microeconomic environments and drivers.
Vaxcell-Bio Therapeutics Predictive Forecast Models
Vaxcell-Bio Therapeutics' time-series forecasting models is one of many Vaxcell-Bio Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Vaxcell-Bio Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Vaxcell-Bio Therapeutics
Checking the ongoing alerts about Vaxcell-Bio Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Vaxcell-Bio Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Vaxcell-Bio Therapeutics generated a negative expected return over the last 90 days | |
| Net Loss for the year was (4.76 B) with loss before overhead, payroll, taxes, and interest of (5.39 M). | |
| Vaxcell Bio Therapeutics Co has accumulated about 27.31 B in cash with (4.66 B) of positive cash flow from operations. | |
| Roughly 14.0% of the company shares are owned by insiders or employees |
Other Information on Investing in Vaxcell-Bio Stock
Vaxcell-Bio Therapeutics financial ratios help investors to determine whether Vaxcell-Bio Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Vaxcell-Bio with respect to the benefits of owning Vaxcell-Bio Therapeutics security.